Zacks: BeyondSpring Inc. (BYSI) Given $56.00 Average Price Target by Brokerages
Shares of BeyondSpring Inc. (NASDAQ:BYSI) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokers have set a one year consensus target price of $56.00 for the company and are predicting that the company will post ($0.79) EPS for the current quarter, according to Zacks. Zacks has also assigned BeyondSpring an industry rank of 98 out of 265 based on the ratings given to related companies.
Several research firms have recently weighed in on BYSI. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of BeyondSpring in a research report on Monday, August 21st. Zacks Investment Research cut shares of BeyondSpring from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Finally, Maxim Group reiterated a “buy” rating and set a $52.00 price objective on shares of BeyondSpring in a research report on Friday, October 27th.
BeyondSpring (BYSI) opened at $32.51 on Tuesday. BeyondSpring has a 12-month low of $16.55 and a 12-month high of $48.49.
BeyondSpring (NASDAQ:BYSI) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. equities research analysts expect that BeyondSpring will post -4.41 earnings per share for the current fiscal year.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.